Charles River Laboratories International announced it has agreed to acquire K.F. (Cambodia) Ltd. for about $510 million and to buy the remaining 79% of PathoQuest SAS for €51.6 million, bringing the combined deal value to roughly $570 million, according to a company statement.
K.F. is a Cambodia-based supplier of non-human primates used in biomedical research, and Charles River said the company has provided more than 30% of its globally sourced non-human primates over the past two years. Charles River expects the K.F. transaction to close in the first quarter of 2026 and to be accretive to non-GAAP earnings per share by about $0.25 in 2026 and $0.60 in 2027.
Separately, Charles River said it exercised an option to acquire PathoQuest, a Paris-based provider of next-generation sequencing solutions for biopharmaceutical quality-control testing. Charles River has owned a 21% stake in PathoQuest since 2018, and expects PathoQuest to generate about $15 million to $20 million in revenue in 2026. The company said this transaction is expected to close by the end of the first quarter of 2026.
Charles River also announced that Dr. Namandjé N. Bumpus will join as senior vice president and chief scientific and innovation officer, after serving as principal deputy commissioner at the U.S. Food and Drug Administration until December 2024. In a separate business update, the company said demand trends improved in its Discovery and Safety Assessment segment in the second half of 2025, citing a preliminary fourth-quarter net book-to-bill estimate of roughly 1.1x, and said foreign-currency translation is expected to lift reported revenue growth by 100 to 150 basis points in 2026.
